Mr. Speaker, I was listening carefully to my colleague's speech. He knows I have an interest in this particular file, and I have more of a comment than a question.
When the member talked about single-payer, streamlining and efficiency when referring to national pharmacare, I hope he does not envision it from the same people who ran Phoenix or the F-35 procurement and who run most of the government. The CRA typically fails at delivering the needed services for taxpayers.
I will give a specific example, because the only time the member mentioned rare diseases was when he was quoting from the Hoskins report. I have an example from my riding where the public health care system failed in my province.
Sharon Lim and Joshua Wong are users of the public health care system. There is a drug approved through CADTH, and there are approved drugs in Canada, but this one is not approved for reimbursement through a public insurer, which I think the national pharmacare system would make even worse. In their particular case, they cannot even get access through the special access program to a competing drug. This is a perfect example of a problem that is unique to the public insurance system, which will be made worse.
I heard the member talk about cost-effectiveness and value for money, but those are decisions that should be made by patients and their doctors, not by bureaucrats in these towers here in Ottawa. This will affect patients with rare diseases such as cystic fibrosis, Alport syndrome and every single rare disease out there.